[Frontiers in Bioscience 16, 3057-3060, June 1, 2011]
G protein-coupled receptor kinases in normal and failing myocardium
Zheng Maggie Huang1, Jessica I Gold1, Walter J Koch1
1
TABLE OF CONTENTS
1. ABSTRACT
Heart failure (HF) is the end stage of many underlying cardiovascular diseases and is among the leading causes of morbidity and mortality in industrialized countries. One of the striking characteristics of HF is the desensitization of G protein-coupled receptor (GPCR) signaling, particularly the β-adrenergic receptor (βAR) system. GPCR desensitization is initiated by phosphorylation by GPCR kinases (GRKs), followed by downregulation and functional uncoupling from their G proteins. In the heart, the major GRK isoforms, GRK2 and GRK5, undergo upregulation due to the heightened sympathetic nervous system activity that is characteristic of HF as catecholamine levels increase in an effort to drive the failing pump. This desensitization leads to the distinctive loss of inotropic reserve and functional capacity of the failing heart. Moreover, GRK2 and GRK5 have an increasing non-GPCR interactome, which may play critical roles in cardiac physiology. In the current review, the canonical GPCR kinase function of GRKs and the novel non-GPCR kinase activity of GRKs, their contribution to the pathogenesis of cardiac hypertrophy and HF, and the possibility of GRKs serving as future drug targets will be discussed.
2. INTRODUCTION
Heart failure (HF) is the end stage of many underlying cardiovascular diseases such as myocardial ischemia, hypertension, valve disease, and congenital malformation. HF is marked by the inability of the heart to adequately pump blood throughout the body. HF is among the leading causes of morbidity and mortality in industrialized countries with 1 in 8.6 death related to HF in 2006 in the United States (1). Regardless of the underlying cause, one striking characteristic of HF is the dysregulation of G protein-coupled receptor (GPCR) signaling, particularly the β-adrenergic receptor (βAR) system. In HF, b1ARs are significantly down regulated and both b1ARs and b2ARs are functionally uncoupled from their G proteins due to increased desensitization by over-active GPCR kinases (GRKs). Other GPCRs in the heart are also likely affected by heightened GRK activity. Hence, signals through all G proteins are altered, including Gq, a nodal signaling switch for adaptive and maladaptive cardiac hypertrophy (2). Receptors implicated in cardiac hypertrophy that have been shown to be GRK targets include a-adrenergic receptors (aARs), angiotensin II receptors (AT1Rs) and endothelin-1 receptors (ET1Rs) (3, 4). The regulation of GPCRs by GRKs in the heart, the corresponding effects on cardiac diseases, and the possibility of GRKs to be future drug targets will be the focus of this review.
3. CARDIAC GPCRS AND GRKS
It is apparent that some of the most important GPCRs in the cardiovascular system are the b AR, the a AR, the AT1R and the ET1R. These receptors individually and collectively regulate cardiac growth and function, including heart rate, contractility, and blood pressure in response to catecholamines and other neurohormones. Since GPCRs are an important factor in the heart's response to stress and injury, they are dynamically regulated to prevent overstimulation. This dampening process, known as desensitization, is initiated through GPCR phosphorylation by second-messenger kinases (for example, protein kinase A (PKA) and protein kinase C (PKC)) or the GRKs. Phosphorylation of GPCRs decreases their affinity to bind and activate G proteins. PKA and PKC initiate heterologous desensitization while GRKs initiate homologous desensitization, phosphorylating only agonist-occupied GPCRs (5).
Seven mammalian GRKs have been characterized to date and can be segregated into three subfamilies: (1) GRK1 and GRK7 (rhodopsin kinase sub-family); (2) GRK2 and GRK3, formerly b -adrenergic receptor kinase 1 and 2, respectively (βARK sub-family); and (3) GRKs 4, 5 and 6 (GRK4-like family) (5). Division into subfamilies is due to differences in expression and receptor specificity (6). This review will focus on GRK2 and GRK5, the predominant GRKs in the heart. Both have been shown to be critical for physiological and pathological cardiac signaling and function and, most importantly, these GRKs are upregulated in the failing heart (7-10).
In general, the GRKs share a tri-domain structure -- a central, strongly conserved catalytic domain homologous to other serine/threonine kinases is flanked by amino and carboxyl termini that vary in structure. These flanking domains contain elements involved in regulation and membrane localization (5, 11). The amino-terminal domain has been proposed to be important for receptor recognition (11), as well as alteration of GRK activity and subcellular localization (12-14). Additionally, GRK2's amino terminus contains a Regulator of G-protein Signaling (RGS) homology domain that has been demonstrated to bind and inactivate Gáq/11 (14). Determination of subcellular localization is the major function of the carboxyl terminus of GRKs. Structural variations in this domain may account for differences in agonist-dependent translocation and receptor specificity. For example, the carboxyl-terminal domain of GRK2 contains a pleckstrin homology (PH) domain that binds the bg-subunit of G proteins (Gbg) (15, 16). Upon GPCR activation and dissociation of Ga from Gbg, this interaction recruits GRK2 to the membrane from its basal location in the cytoplasm (17). Distinctively, GRK5 does not contain a PH domain, and remains bound constitutively to the plasma membrane via a carboxyl terminus amphipathic helix and phosphatidylinositol 4,5-bisphosphate (PIP2) binding domains (13, 18) (Figure 1). In addition, GRK5 contains a functional nuclear localization signal (NLS) within its central catalytic domain (19, 20). GRK2 and GRK5 do share some properties that will be highlighted below including the fact that they themselves can be regulated by kinases such as PKC (21).
The pathway of homologous b AR desensitization is best demonstrated by the activity of the ubiquitously expressed GRK2, the major GRK isoform in the heart. GRK2 is primarily cytosolic under basal conditions and upon GPCR activation GRK2 translocates to where the receptor is located via binding to the membrane-bound Gbg. Following GRK phosphorylation, b -arrestin binds to the receptor, sterically hindering interactions between the receptor and the G proteins and resulting in desensitization within milliseconds to minutes of GPCR activation (22). In addition, b -arrestin-bound receptors are internalized to intracellular lysosomes and degraded, leading to receptor downregulation at the plasma membrane (23) (Figure 2). Importantly, the Gbg-mediated translocation of GRK2 has been exploited to generate a potent inhibitor of GRK2 activation as a polypeptide comprised of the last 194 amino acids of GRK2, known as the b ARKct, has been shown to compete with endogenous GRK2 for Gb g binding, preventing GPCR desensitization both in vitro and in vivo (16, 24). GRK5, on the other hand, does not need to undergo translocation prior to receptor targeting as it is constitutively membrane associated (25). Despite similar roles in GPCR desensitization, studies of GRK2 and GRK5 in the heart using genetically engineered mice show distinct phenotypes, especially concerning maladaptive hypertrophy and HF. In fact, differences in their activity in the heart make both of these GRKs exciting targets for novel therapeutic strategies for heart diseases.
4. GRK2 AND ITS ROLE IN CARDIAC PHYSIOLOGY AND PATHOPHYSIOLOGY
4.1. GRK2-targeted engineered mice
The importance of GRK2 in the regulation of cardiac contractile function has been documented primarily by studies in genetically engineered mice (Table 1). When GRK2 was disrupted globally by homologous recombination in mice, no GRK2-/- animals survived beyond gestational day 15.5 (26). Interestingly, GRK2-/- embryos displayed pronounced hypoplasia of the ventricular myocardium, and in utero intravital microscopy showed that GRK2-/- embryos exhibited a >70% decrease in cardiac ejection fraction, suggesting cardiac failure (26). Importantly, heterozygous knockout mice (KO), with 50% levels of GRK2 in myocardium, showed increased contractile function in both whole animal and single isolated myocytes (26). More recently, conditional, cardiac-specific GRK2 KO mice using GRK2floxed mice and Cre recombinase driven by the Nkx2.5 promoter developed normally, which shows that the developmental defect in the global GRK2 KO mice was not cardiac autonomous (27). These cardiac-specific KO mice did have increased cardiac damage due to chronic treatment with the bAR agonist isoproterenol (Iso) demonstrating that under these non-physiological stress conditions, the loss of receptor desensitization can promote injury (27). GRK2 has been deleted in cardiac myocytes of adult mice using Cre recombinase driven by the aMHC promoter that is either constitutively active or inducible (MerCreMer) with tamoxifen (28). These mice have increased function consistent with heterozygous global KO mice and actually averted HF development (discussed in more detail below) (28).
Transgenic mice with altered GRK2 activity have also been developed. Cardiac-specific GRK2 overexpressing mice were generated over a decade ago. These mice displayed a loss of bAR-mediated inotropic reserve (24) and augmented AT1R desensitization in their hearts (29). Cardiac-targeted bARKct mice have also been extensively studied. These were the first mice used to demonstrate the powerful effect of GRK2 activity on cardiac function as these mice has increased function throughout their lives without demonstrating any myocardial damage (24). These mice have also rescued several mouse models of HF (see below). Mice with cardiac overexpression of an amino-terminal peptide of GRK2 (b ARKnt), which did not include the entire RGS domain, exhibited cardiac hypertrophy, even though there is no dampening of Gq-mediated hypertrophic signaling (30). Overall, these mouse models illustrate the importance of GRK2 in modulating myocardial contractile function and growth. As discussed in more detail below, these models provide excellent tools for investigating the regulation of b AR signaling and cardiac function under pathological conditions.
4.2. b ARs and GRK2 in failing myocardium
In the heart, b 1ARs are the predominant isoform, comprising about 75-80% of total b ARs. b 2ARs and b 3ARs are also expressed (31). The principle function of b ARs in the heart is to increase the rate and force of cardiac myocyte contraction following activation by the catecholamines epinephrine (Epi) and norepinephrine (NE). Consequently, pharmacological interventions to stimulate b ARs have been used to increase cardiac function in conditions of pump failure. However, long-term usage of b-agonists in conditions such as HF has proven lethal due to catecholamine toxicity (32, 33). On the other hand, and initially counter-intuitive, bAR antagonists can improve mortality and function of the failing heart and are currently standards of care of this condition (32, 34).
The negative outcomes of b-agonists could be due to differential signaling between b1ARs and b2ARs in myocardium. To address this point, transgenic mouse models have been used and directly demonstrate that b1AR signaling in the heart is generally toxic while b2AR signaling can promote myocyte survival, interestingly, through Gi coupling (35-39). Alternatively, b-agonists may be toxic due to the dysfunctional state of bARs in failing myocardium. In HF, myocardial b1ARs are selectively downregulated by 50% and remaining b1ARs and b2ARs are desensitized (31, 40). This leads to the characteristic loss of inotropic reserve and functional capacity of the failing heart (40). The loss of bAR function is no doubt initiated through heightened sympathetic nervous system activity characteristic of HF as catecholamine levels are increased in efforts to drive the failing pump (41).
The mechanistic link between hyperactive sympathetic nervous system activation and bAR dysfunction is apparently increased GRK2 expression (as well as GRK5 perhaps - see below). GRK2 is increased at the mRNA, protein and activity level in failing human myocardium (7), and is shown to be increased almost immediately after cardiac injury such as myocardial infarction (MI) by coronary artery ligation (42), global ischemia (43), and pressure overload induced hypertrophy (44, 45). In all cases, heightened GRK2 activity causes b AR desensitization. A model to explain this - as the heart fails, desensitization of the b ARs by GRK2 leads to insufficient cardiac output activating compensatory mechanisms that chiefly increase catecholamine excretion. This further increases GRK2 expression and facilitates b ARs desensitization (44, 46, 47). The vicious cycle eventually leads to deterioration of heart function and facilitates HF progression. The success of b -blockade in treating chronic HF in clinical practice supports the maladaptive nature of b AR desensitization. Indeed, chronic treatment of mice with b -blockers decreases GRK2 expression in the heart (46). Combined with the generally favorable effects of GRK2 lowering in HF models, (see below) this could represent a novel action of b-blockers that contributes to their success in HF.
Since GRK2 is elevated after myocardial injury and remains elevated chronically in HF, studies have begun to address whether this could be a novel biomarker to evaluate ventricular dysfunction in human disease. Importantly, levels of GRK2 in peripheral lymphocytes have been shown to mirror cardiac levels (48, 49). Indeed, lymphocyte levels of GRK2 are elevated in human HF patients (49) and interestingly, in human hypertensive patients, mimicking GRK2 up-regulation during cardiac stress (50). The mirrored levels of GRK2 in white blood cells and cardiac tissue were best illustrated in our study where LV and blood samples from the same patient were examined for GRK2 (48). In this study, patients with chronic HF undergoing surgery for a LV mechanical assist device (LVAD) were evaluated for blood and cardiac GRK2 levels before and 2-3 months after mechanical unloading (48). LVAD implantation was found to lower GRK2 levels in myocardium as well as in lymphocytes, and corresponded with mechanical unloading of the heart improving bAR signaling and contractile function (48). Further, there was a significant positive correlation between myocardial and lymphocyte GRK2 levels in both HF and LVAD samples. Thus, lymphocyte GRK2 may serve as a surrogate marker of myocardial GRK2 in these patients (48). In a more recent study, blood from 24 HF patients before and after heart transplantation was analyzed and followed up to 1 year. Lymphocyte GRK2 significantly dropped, remained low, and correlated with improved cardiac function in the transplanted heart, indicating the potential of using lymphocyte GRK2 to predict cardiac function at end stage HF, and to possibly evaluate the effectiveness of the therapy regimen (51).
4.3. Cardiac GRK2 as a Therapeutic Target
Since mice with 50% cardiac GRK2 expression and bARKct transgenic mice had enhanced cardiac contractile function, the hypothesis that targeting GRK2 may improve HF was tested. In fact, the first rescue of a genetic mouse model of HF was demonstrated using the bARKct mice (52). In this study, KO mice for the muscle-LIM protein, which present with a dilated cardiomyopathic phenotype, were bred with βARKct transgenic mice. The resultant hybrid mice had no signs of HF (52). Other genetic models of HF were also rescued by βARKct expression (53, 54). One interesting study involved the combined use of bARKct expression with b-blockade in a model of hypertrophic HF. b ARKct mice were crossed with transgenic mice with cardiac overexpression of the sarcoplasmic reticulum Ca2+-binding protein calsequestrin (CSQ) (53). CSQ mice have severe cardiomyopathy and shortened survival (9± 1 weeks). The b ARKct/CSQ hybrid mice exhibited significant enhancement in survival age to about 15 weeks (46). Cardiac b ARKct expression attenuated cardiac remodeling of CSQ mice, as demonstrated by smaller LV end diastolic dimension, LV end systolic dimension, and maintenance of LV wall thickness, accompanied by improved LV fractional shortening. Biochemically, despite decreased membrane b AR density, b ARKct induced an increase in the percentage of b ARs in the high-affinity state (46). More importantly, b ARKct and b -blocker metoprolol had an additive effect with regard to cardiac function (46). These data demonstrated that inhibition of GRK2 is beneficial in established HF models, and could provide additional benefit to b -blocker therapy. The beneficial mechanism of bARKct is sequestering Gbg and thus inhibiting GRK2 activity. This was directly tested in bARKct transgenic heart lysate. Addition of Gbg showed significantly less rhodopsin phosphorylation, namely lower GRK2 activity, as compared to without Gbg (24). Whether bARKct has other effects independent of Gbg warrants further investigation.
The bARKct mice themselves have been shown to exert therapeutic effects in surgically induced HF models. In fact, a positive gene-dosage effect has been seen with cardiac bARKct expression. Transgenic mice with low bARKct expression developed severe HF 12 weeks after LV pressure overload induced by transverse aortic constriction (TAC), whereas mice with high bARKct expression showed significantly less cardiac deterioration than WT mice (55). Importantly, high levels of myocardial bARKct preserved Iso-stimulated adenylyl cyclase activity and bAR densities in cardiac membranes (55), demonstrating that the level of GRK2 inhibition determines cardiac function. In a different mouse model, bARKct transgene expression was driven under the control of the cardiac ankyrin repeat protein (CARP) promoter, which is active during cardiac development and quiescent in normal adult heart (45). CARP is a fetal gene that is activated during cardiac diseases, like hypertrophy. As a result, when the CARP-βARKct mice underwent TAC, bARKct expression was acutely induced, preventing the loss of bAR responsiveness during hypertrophy, despite upregulated GRK2, as well as ameliorating HF development (45). These results demonstrated that acute GRK2 inhibition could restore lost myocardial βAR responsiveness in vivo (45).
Since bARKct works via Gbg sequestration, there could be non-GRK2 effects contributing to the remarkable HF rescue data presented above. Other potential Gbg targets include activation of phosphatidylinositol 3-kinase (PI3K) (56) and acetylcholine activated K+ channels (IK,Ach) (57). In addition, it is possible that βARKct inhibits the phosphorylation of other GPCRs since GRK2 has many receptor targets in the heart. Accordingly, to further elucidate that GRK2 is the critical molecule mediating ventricular maladaptation, cardiac-specific GRK2 KO mice were subjected to MI to induce HF (28). In one set of experiments, mice with cardiomyocyte GRK2 loss at birth were observed for 28 days after MI to note any phenotypic changes. GRK2 KO mice showed better survival, despite a similar infarct size (28). Analysis of hemodynamics showed that GRK2 KO mice had better preserved βAR signaling post MI, as compared to control mice. GRK2 KO mice also had less remodeling as reflected by heart weight to body weight ratio, and less fetal gene activation. The protective phenotype was explained at isolated single cell level, since GRK2 KO myocytes from post MI heart displayed better contraction (28). The results directly demonstrated that minimizing GRK2 activity prevents or delays the occurrence of HF (28). In a second set of experiments, inducible cardiac GRK2 KO mice were studied. Mice were subjected to MI producing LV dysfunction and remodeling. Next, GRK2 gene deletion was induced (28). Following the loss of GRK2 in myocytes, post-MI mice stopped dying, had significantly improved cardiac function and underwent an active reverse remodeling process (28). This data clearly shows that in the setting of ischemic-HF, GRK2 is pathological and its loss actively reverses LV dysfunction. At least in the small animal setting, GRK2 is a profound target for HF therapy (28). Moreover, it indicates that bARKct apparently targets GRK2 inhibition as its primary mechanisms of action since KO and bARKct phenotypes in HF are so similar. Thus, bARKct delivery and expression in the heart appears to represent a potential therapeutic strategy in HF that has indeed been tested using gene therapy approaches (discussed below).
4.4. Cardiac GRK2 Inhibition with Gene Therapy
To make targeting GRK2 more relevant to clinical practices, bARKct delivery has been used in larger animal models of HF. Early studies used adenoviral vectors. For example, in failing myocytes isolated from spontaneously hypertensive heart failure (SHHF) rats, adenovirus-mediated bARKct overexpression led to significant increases in basal and bAR-stimulated cAMP production, at rates even higher than non-failing myocytes (47). Single cell shortening, relaxation, and contraction were also improved by bARKct. Importantly, more recent studies have shown similar results in failing human ventricular myocytes (58). The acute therapeutic efficacy of adenoviral-delivered bARKct has also been shown in several other HF models (rats, rabbits and hamsters) during MI (59), post cardioplegic arrest (60), HF induced by pacing (61), or cardiomyopathic mice with overexpression of a myosin heavy chain gene mutant (54).
The studies using adenovirus demonstrated positive results but had limitations, since adenoviruses support only short-term bARKct expression in the heart in vivo. Therefore, to determine clinical relevance, new vectors were needed. This has recently been solved through the use of adeno-associated viral (AAV) vectors, which appear extremely amenable for human use in chronic diseases, such as HF, because they support chronic transgene expression with limited immune problems (62, 63). Recently, a clinically relevant HF study was carried out in rats where AAV6-bARKct was delivered to the post-MI failing rat heart (64). Echocardiography confirmed compromised heart function and remodeling 12 weeks after a cryo-infarction. AAV6-bARKct was then directly delivered to the heart, and rats were followed chronically for 3 months. Echocardiography showed that bARKct improved cardiac contractility and even reversed LV remodeling, while hearts received control virus continued deteriorating (64). The protection by bARKct was accompanied by a normalization of the neurohormonal (catecholamine and aldosterone) status of the chronic HF animals including normalization of bAR signaling (64). These results demonstrate the potential for bARKct gene therapy, which is currently being tested by us in large animal pre-clinical models of HF.
4.5. Novel regulation of GRK2 activity
Since GRK2 appears to play a crucial role in cardiac physiology and pathophysiology, it is of great importance to elucidate the cellular mechanisms that regulate GRK2 function. Attention has been given to the post-translational modification of GRK2, primarily via phosphorylation and S-nitrosylation. There are three major phosphorylation sites on GRK2, a PKC site at Ser29, an ERK site at Ser670 (65), and a PKA site at Ser685 (66). PKC phosphorylation activates GRK2 (67, 68) by abolishing the inhibitory effect of Ca2+/camodulin on GRK2 (69). It has recently been reported that PKC phosphorylation of GRK2 at Ser29 accounts for impaired b AR signaling after mechanical stretch, which is upstream of the Gq pathway (70). The crosstalk between hypertrophic Gq and Gs pathways might be an important mechanism for the transition from hypertrophy to HF. ERK phosphorylation of GRK2 at Ser670, on the other hand, inhibits its membrane translocation and hence its GPCR activity (65).
It was reported recently that GRK2 could be S-nitrosylated, with the primary site being Cys340 (71). Thus, in addition to multiple GPCRs (such as the b2AR (72) and AT1R) (73) that are also targets of nitrosylating agents, Targeting GRK2 adds complexity to nitric oxide synthase (NOS) - NO system regulation of cellular signaling. Interestingly, S-nitrosylation of GRK2 attenuates its activity on βAR signaling and other down-stream targets (71). In mice, reduced NO production by the NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) accelerated βAR desensitization in the heart in vivo as determined by LV dP/dtmax within 30 min of isoproterenol treatment (71). Further, NO bioavailability preserves bAR signaling in the heart through GRK2 inhibition. Consistent with this, mice with more endogenous NO due to deficient breakdown of active GSNO, display increased membrane bAR density (74). Also, mechanistic studies in cells demonstrated that NO donors inhibited GRK2 mediated events, including bAR phosphorylation and subsequent b-arrestin binding to the receptor as measured by FRET, cAMP production, and receptor internalization (71). In addition to GRK2, other proteins involved in endocytosis, like b-arrestin (75) and dynamin (76), are also S-nitrosylated. This novel form of post-translational regulation has important therapeutic significance, as during HF, there is both deficiency of NO and desensitized bAR signaling. Thus, supplementation of NO donors may also serve to inhibit GRK2 and restore bAR signaling. On the other hand, the deficiency of NO bioactivity and, thus, less endogenous GRK2 inhibition, may be another mechanism for disturbed GPCR signaling during HF. Studies investigating the functional effects of S-nitrosylation on GRK2 during diseased states will provide more insights into the benefits of manipulating this regulation (71).
4.6. GPCR independent functions of GRK2 in the heart
In addition to its classical GRK activity, emerging new data suggests that GRK2 may have functions independent from its actions on GPCRs. The recent concept of an extensive "GRK2 interactome" points to the possibility that GRK2 may exert its functions by interacting with other intracellular proteins (77). For example, GRK2 interacts and phosphorylates tubulin in bovine brain (78), which facilitates the polymerization of tubulin into microtubules (79). It has been reported that an increased ratio of microtubules to tubulin in the heart is pro-hypertrophic (80). Whether the regulation of tubulin by GRK2 in the heart has functional significance merits further investigation. Emphasizing the potential importance of GRK2 in cardiac hypertrophy, it has been shown that GRK2 can influence the cell cycle of certain cells and that cell cycle kinases can regulate GRK2 itself (81). This has yet to be seen in myocytes but presents an intriguing scenario if this is true.
An interesting recent finding in liver endothelial cells shows GRK2 inhibiting the kinase, Akt (82). Akt is an important survival kinase and a strong activator of endothelial NOS (eNOS) (83, 84). Whether GRK2 could induce changes in Akt and eNOS activity in the heart could explain the phenotypic changes in GRK2 transgenic mice. This obviously has additional importance due to the novel effects of S-NO on GRK2 discussed above. Other potential binding partners of GRK2 reported so far include: caveolin (85), clathrin (86) and ERK1/2 (65). Overall, several of the proteins shown to be present in a dynamic GRK2 interactome may be important in cardiac physiology and pathophysiology, indicating that the beneficial effects of GRK2 targeting in HF extend well beyond the reversal of βAR dysfunction. Future experiments will deal with the mechanistic potential of GPCR independent effects of GRK2 in the heart.
4.7. Adrenal GRK2 and HF
As mentioned above, one of the prominent features of HF is increased circulating catecholamines including Epi and NE, due to sympathetic nerve system hyperactivity. While NE is secreted by sympathetic nerve terminals, Epi is mainly secreted by the chromaffin cells of adrenal medulla. The secretion of Epi is tightly regulated by a 2ARs, which serve as a presynaptic negative feedback mechanism. Recent work in our lab demonstrated that in animal models of HF, adrenal GRK2 upregulation led to downregulation and uncoupling of a 2ARs and elevated circulating catecholamines as a result of losing the inhibitory feedback (87). Adrenal b ARKct gene delivery post-MI rescued both the adrenal and cardiac dysfunction (87, 88). Furthermore, chromaffin cell-specific GRK2 KO exhibited decreased circulating catecholamines post-MI and better cardiac function, suggesting the potential of adrenal GRK2 as a therapeutic target for HF (89).
5. THE ROLE OF GRK5 IN MALADAPTIVE HYPERTROPHY AND HF
5.1. GRK5-Targeted Engineered Mice Although GRK5 has not been as extensively studied as GRK2 in myocardium, it has also been found to be upregulated in HF, including in humans (8-10). Studies in cardiac-targeted GRK5 overexpressing transgenic mice have found that this GRK can desensitize distinct receptors compared to GRK2, although they both share in the regulation of cardiac βARs (90, 91). Indeed, GRK5 transgenic mice have blunted in vivo inotropic responses to βAR stimulation similar to GRK2 overexpression (29). However, in contrast to reduced cardiac AT1R signaling in GRK2 transgenic mice, GRK5 mice had normal in vivo functional responses to angiotensin II, showing the first GPCR selectivity by these two GRKs (29). Divergent receptor specificity was also demonstrated for the α1BAR in vivo, with GRK5 showing partial desensitization and GRK2 displaying no inactivation effects (91). The ability of GRK2 and 5 to desensitize specific GPCRs suggests overlapping, but distinct roles of these predominant cardiac GRKs.
5.2. Role of GRK5-mediated non-cannonical signaling in HF
Characterization of GRK distribution in SHHF rats uncovered novel nuclear localization of GRK5 (92). Cardiomyocytes isolated from SHHF rats display significant redistribution of GRK5 in the nucleus, while myocytes from wild-type Wistar rats show diffuse distribution throughout the cytoplasm (75). This nuclear accumulation is unique to GRK5 as staining for GRK2 shows a diffuse cytoplasmic distribution in both the SHHF rats and the Wistar rats (92, 93). It was then discovered that GRK5 has a functional NLS within its catalytic domain, as well as a putative nuclear export sequence (NES) (19). To demonstrate the functional capacity of the catalytic domain NLS to guide GRK5 into the nucleus, a mutant GRK5 was generated by mutating the basic residues within its NLS to alanines. This mutant GRK5 was unable to enter the nucleus (19). Additionally, the NLS of GRK5 shows homology to the DNA binding NLS of homeobox transcription factors, and is able to selectively bind single-stranded DNA, suggesting a possible role of GRK5 as a transcription factor (19).
In regards to HF, a very exciting and potential significant role for nuclear GRK5 has recently been elucidated. Following TAC surgery in mice, or Gq-stimulation, nuclear accumulation of GRK5 increases (20). In fact, in cardiac-targeted GRK5-overexpressing transgenic mice TAC-induced hypertrophy and subsequent HF was significantly exaggerated and accelerated (20). Interestingly, nuclear GRK5 accumulation leads to increased cardiomyocyte growth via augmented activity of myocyte elongation factor 2 (MEF2), a transcription factor critical for cardiac development and growth (94). We found that GRK5 has novel histone deacetylase (HDAC) kinase activity in the nucleus and phosphorylates HDAC5, a class II HDAC that represses MEF2 activity in the heart (95, 96). Thus, increased activity of GRK5 in the nucleus of myocytes enhances MEF2 activity and appears to participate in maladaptive cardiac hypertrophy. Interestingly, GRK5 nuclear accumulation and HDAC kinase activity lie downstream of activated Gq. The post-Gq and hypertrophic signaling pathways that induce GRK5 accumulation in the nucleus remain to be determined (Fig 3). The role of nuclear GRK5 in promoting cardiac hypertrophy and HF was recapitulated in vivo with the generation of a transgenic mouse expressing a mutant GRK5 devoid of a functional NLS (ΔNLS). Compared to wild-type mice, the ΔNLS mice show no difference in cardiac hypertrophy or function at four weeks post-TAC (20). Recent data from our lab reinforces this injurious role of cardiac GRK5, as global GRK5 KO mice, which have no basal cardiac phenotype, demonstrate attenuated hypertrophy and normal cardiac function when compared to WT at 12 weeks post-TAC (Koch lab, unpublished data). However, the exact role of cardiomyocyte-specfic GRK5 deletion remains uncharacterized.
5.3. Human Polymorphisms of GRK5
A recent discovery has strengthened the clinical significance of GRK5 in HF. Liggett et al. recently uncovered a single nucleotide polymorphism (SNP) in GRK5 that protects against catecholamine toxicity associated with HF (97). Common among African Americans, this amino terminal SNP creates a glutamine to leucine switch at amino acid position 41 of GRK5. Transgenic mouse models with low and comparable levels of cardiac GRK5Glu41 and GRK5Leu41 reveal a protective effect of GRK5Leu41 following chronic infusion of Iso via mini-osmotic pump (97). The GRK5Leu41 transgenic mice show less cardiac remodeling with smaller heart weights and decreased alterations in LV end diastolic diameter. These beneficial effects in mice appear to be translated to African American HF patients. Without b-blocker treatment, patients with the GRK5Leu41 allele show prolonged survival or time to cardiac transplant compared to b-blocker naïve patients expressing the GRK5Glu41 allele (97). The effects of the GRK5Leu41 allele mirror the effects of β-blocker treatment in patients with the GRK5Glu41 allele, yet there is no additive effect of b-blocker treatment in the GRK5Leu41-expressing patients (97). This "genetic bAR blockage" expounds the importance of decreased bAR stimulation in HF. Interestingly, the mutation's position, at amino acid 41, abuts an important calmodulin regulatory region (5, 98, 99). Calmodulin has been shown to decrease GRK5's plasma membrane association and increase GRK5's kinase activity on cytoplasmic substrates (98). Decreased affinity for calmodulin by the Q41L mutation may cause increased plasma membrane association and heightened desensitization of bARs.
6. CONCLUSIONS
Despite the apparent similarities in structure and function of GRK2 and GRK5, these kinases fulfill non-redundant roles in the heart. Distinct phenotypes displayed in genetically engineered mice and surgically acquired models of cardiac injury, in addition to differential regulation of GRK2 and GRK5 in HF, demonstrate that both of these GRKs deserve to be considered as potential therapeutic targets for alleviating maladaptive cardiac hypertrophy and HF. To note, an interesting divergence between GRK2 and GRK5 lies in their subcellular localization. As discussed above, GRK2 displays diffuse cytoplasmic distribution basally. GPCR activation targets GRK2 to the plasma membrane via various interactions at its carboxyl terminal. On the other hand, GRK5 is constitutively membrane-associated via its carboxyl terminal. However, agonist binding to specific GPCRs, likely receptors that couple to Gq, promotes membrane dissociation of GRK5 and translocation into the nucleus. In both cases, the GRK's subcellular locale relates to its role in HF pathology. Decreasing GRK2 recruitment to the membrane by expression of bARKct rescues cardiomyocytes from dysregulation, and ameliorates functional loss after cardiac injury. The relationship between GRK5 localization and cardiac pathology appears to mirror that of GRK2, however, instead of increased GRK5 at the plasma membrane being pathological, the accumulation of GRK5 in the nuclear compartment of myocytes is detrimental to cardiac function. Additionally, plasma membrane-associated GRK5 may be beneficial for preserving function in the face of cardiac insult. Recent data has suggested that GRK5 plays a role in EGFR transactivation, protecting the heart against ischemic injury through increased EGF signaling (100). In a similar vein to bARKct, the development of a therapeutic intervention that prevents the nuclear accumulation of GRK5 may show beneficial effects in the treatment of HF.
In dissecting the differences between GRK2 and GRK5, it is also important to note discrepancies in their regulation by kinases and other effector molecules. These molecules likely participate in the differential subcellular domain targeting and modulation of kinase activity of the GRKs. For example, both GRK2 and GRK5 contain calmodulin binding sites at their amino termini, and both GRKs show decreased GPCR phosphorylation following calmodulin binding. The extent of calmodulin's inhibition is significantly greater for GRK5 than GRK2 (69, 98). Carboxyl terminal phosphorylation by PKC relieves this inhibition for GRK2, while further decreasing GRK5's kinase activity on membrane-associated and cytoplasmic substrates (21, 69). Furthermore, GRK5 displays the ability to autophosphorylate at its carboxyl terminal, following stimulation by either phospholipids or calmodulin (12, 98). The differences in regulation outlined above, among others, may help explain the non-overlapping roles of the two primary cardiac GRKs.
As outlined in this review, GRK2 and GRK5 are intriguing targets for future HF therapy. Experiments with bARKct demonstrate an extremely promising role for inhibiting GRK2 in order to prevent HF and rescue diseased cardiomyocytes. Further study into the mechanism of GRK5 nuclear accumulation will allow for development of intervening agents. Overall, future research on the classical and non-cannonical roles of GRK2 and GRK5 in HF as well as delving deeper into the translational significance of the ever increasing "interactomes" will likely continue to uncover the importance of these two GRKs in the pathogenesis of cardiac disease.
7. ACKNOWLEDGEMENT
WJK is supported by NIH grants R37 HL061690, R01 HL58803, P01 091799 and P01 HL075443 (Project 2), ZMH is supported by a post-Doctoral Fellowship from the American Heart Association (Great Rivers Affiliate), and JIG is supported by a Pre-Doctoral Fellowship from the American Heart Association (Great Rivers Affiliate).
7. REFERENCES
1. M. Writing Group, D. Lloyd-Jones, R. J. Adams, T. M. Brown, M. Carnethon, S. Dai, G. De Simone, T. B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P. M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V. L. Roger, W. Rosamond, R. Sacco, P. Sorlie, R. Stafford, T. Thom, S. Wasserthiel-Smoller, N. D. Wong, J. Wylie-Rosett, C. on behalf of the American Heart Association Statistics and S. Stroke Statistics: Executive Summary: Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association. Circulation, 121, 948-954 (2010)
PMid:20177011
2. S. A. Akhter, L. M. Luttrell, H. A. Rockman, G. Iaccarino, R. J. Lefkowitz and W. J. Koch: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science, 280, 574-577 (1998)
doi:10.1126/science.280.5363.574
PMid:9554846
3. J. Heineke and J. D. Molkentin: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol, 7, 589-600 (2006)
doi:10.1038/nrm1983
PMid:16936699
4. J. D. Molkentin and G. W. Dorn, 2nd: Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol, 63, 391-426 (2001)
doi:10.1146/annurev.physiol.63.1.391
PMid:11181961
5. J. A. Pitcher, N. J. Freedman and R. J. Lefkowitz: G protein-coupled receptor kinases. Annu Rev Biochem, 67, 653-692 (1998)
doi:10.1146/annurev.biochem.67.1.653
PMid:9759500
6. R. T. Premont and R. R. Gainetdinov: Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol, 69, 511-534 (2007)
doi:10.1146/annurev.physiol.69.022405.154731
PMid:17305472
7. M. Ungerer, M. Bohm, J. S. Elce, E. Erdmann and M. J. Lohse: Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation, 87, 454-463 (1993)
PMid:8381058
8. L. E. Vinge, E. Oie, Y. Andersson, H. K. Grogaard, G. Andersen and H. Attramadal: Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol, 281, H2490- H2499 (2001)
9. N. Dzimiri, C. Basco, A. Moorji, B. Afrane and Z. Al-Halees: Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol, 29, 181-188 (2002)
doi:10.1046/j.1440-1681.2002.03625.x
PMid:11906480
10. N. Dzimiri, P. Muiya, E. Andres and Z. Al-Halees: Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol, 489, 167-177 (2004)
doi:10.1016/j.ejphar.2004.03.015
PMid:15087239
11. J. Inglese, N. J. Freedman, W. J. Koch and R. J. Lefkowitz: Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem, 268, 23735-23738 (1993)
PMid:8226899
12. P. Kunapuli, V. V. Gurevich and J. L. Benovic: Phospholipid-stimulated autophosphorylation activates the G protein-coupled receptor kinase GRK5. J Biol Chem, 269, 10209-10212 (1994)
PMid:8144599
13. A. N. Pronin, C. V. Carman and J. L. Benovic: Structure-function analysis of G protein-coupled receptor kinase-5. Role of the carboxyl terminus in kinase regulation. J Biol Chem, 273, 31510-31518 (1998)
doi:10.1074/jbc.273.47.31510
PMid:9813065
14. M. Sallese, L. Iacovelli, A. Cumashi, L. Capobianco, L. Cuomo and A. De Blasi: Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. Biochim Biophys Acta, 1498, 112-121 (2000)
PMid:11108955
15. J. A. Pitcher, J. Inglese, J. B. Higgins, J. L. Arriza, P. J. Casey, C. Kim, J. L. Benovic, M. M. Kwatra, M. G. Caron and R. J. Lefkowitz: Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science, 257, 1264-1267 (1992)
doi:10.1126/science.1325672
PMid:1325672
16. W. J. Koch, J. Inglese, W. C. Stone and R. J. Lefkowitz: The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem, 268, 8256-8260 (1993)
PMid:8463335
17. H. Brinks and W. J. Koch: betaARKct: A Therapeutic Approach for Improved Adrenergic Signaling and Function in Heart Disease. J Cardiovasc Transl Res doi:10.1007/s12265-010-9206-6
PMid:20623214
18. M. M. Thiyagarajan, R. P. Stracquatanio, A. N. Pronin, D. S. Evanko, J. L. Benovic and P. B. Wedegaertner: A predicted amphipathic helix mediates plasma membrane localization of GRK5. J Biol Chem, 279, 17989-17995 (2004)
doi:10.1074/jbc.M310738200
PMid:14976207
19. L. R. Johnson, M. G. Scott and J. A. Pitcher: G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol Cell Biol, 24, 10169-10179 (2004)
doi:10.1128/MCB.24.23.10169-10179.2004
PMid:15542828 PMCid:529036
20. J. S. Martini, P. Raake, L. E. Vinge, B. R. DeGeorge, Jr., J. K. Chuprun, D. M. Harris, E. Gao, A. D. Eckhart, J. A. Pitcher and W. J. Koch: Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A, 105, 12457-12462 (2008)
doi:10.1073/pnas.0803153105
PMid:18711143 PMCid:2527933
21. A. N. Pronin and J. L. Benovic: Regulation of the G protein-coupled receptor kinase GRK5 by protein kinase C. J Biol Chem, 272, 3806-3812 (1997)
doi:10.1074/jbc.272.29.18273
PMid:9218466
22. M. J. Lohse, S. Andexinger, J. Pitcher, S. Trukawinski, J. Codina, J. P. Faure, M. G. Caron and R. J. Lefkowitz: Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. J Biol Chem, 267, 8558-8564 (1992)
PMid:1349018
23. W. P. Hausdorff, M. G. Caron and R. J. Lefkowitz: Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J, 4, 2881-2889 (1990)
PMid:2165947
24. W. J. Koch, H. A. Rockman, P. Samama, R. A. Hamilton, R. A. Bond, C. A. Milano and R. J. Lefkowitz: Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science, 268, 1350-1353 (1995)
doi:10.1126/science.7761854
PMid:7761854
25. R. T. Premont, W. J. Koch, J. Inglese and R. J. Lefkowitz: Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem, 269, 6832-6841 (1994)
PMid:8120045
26. M. Jaber, W. J. Koch, H. Rockman, B. Smith, R. A. Bond, K. K. Sulik, J. Ross, Jr., R. J. Lefkowitz, M. G. Caron and B. Giros: Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci U S A, 93, 12974-12979 (1996)
doi:10.1073/pnas.93.23.12974
27. S. J. Matkovich, A. Diwan, J. L. Klanke, D. J. Hammer, Y. Marreez, A. M. Odley, E. W. Brunskill, W. J. Koch, R. J. Schwartz and G. W. Dorn, 2nd: Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res, 99, 996-1003 (2006)
doi:10.1161/01.RES.0000247932.71270.2c
PMid:17008600
28. P. W. Raake, L. E. Vinge, E. Gao, M. Boucher, G. Rengo, X. Chen, B. R. DeGeorge, Jr., S. Matkovich, S. R. Houser, P. Most, A. D. Eckhart, G. W. Dorn, 2nd and W. J. Koch: G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res, 103, 413-422 (2008)
doi:10.1161/CIRCRESAHA.107.168336
PMid:18635825 PMCid:2679955
29. H. A. Rockman, D. J. Choi, N. U. Rahman, S. A. Akhter, R. J. Lefkowitz and W. J. Koch: Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A, 93, 9954-9959 (1996)
doi:10.1073/pnas.93.18.9954
30. J. R. Keys, E. A. Greene, C. J. Cooper, S. V. Naga Prasad, H. A. Rockman and W. J. Koch: Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ARK1. Am J Physiol Heart Circ Physiol, 285, H2201-H2211 (2003)
31. O. E. Brodde, H. Bruck and K. Leineweber: Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci, 100, 323-337 (2006)
doi:10.1254/jphs.CRJ06001X
PMid:16612046
32. J. D. Port and M. R. Bristow: Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol, 33, 887-905 (2001)
doi:10.1006/jmcc.2001.1358
PMid:11343413
33. G. Rona: Catecholamine cardiotoxicity. J Mol Cell Cardiol, 17, 291-306 (1985)
doi:10.1016/S0022-2828(85)80130-9
34. M. Packer, M. R. Bristow, J. N. Cohn, W. S. Colucci, M. B. Fowler, E. M. Gilbert and N. H. Shusterman: The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med, 334, 1349-1355 (1996)
doi:10.1056/NEJM199605233342101
PMid:8614419
35. S. Engelhardt, L. Hein, F. Wiesmann and M. J. Lohse: Progressive hypertrophy and heart failure in α-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A, 96, 7059-7064 (1999)
doi:10.1073/pnas.96.12.7059
36. C. A. Milano, L. F. Allen, H. A. Rockman, P. C. Dolber, T. R. McMinn, K. R. Chien, T. D. Johnson, R. A. Bond and R. J. Lefkowitz: Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science, 264, 582-586 (1994)
doi:10.1126/science.8160017
PMid:8160017
37. G. W. Dorn, 2nd, N. M. Tepe, J. N. Lorenz, W. J. Koch and S. B. Liggett: Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A, 96, 6400-6405 (1999)
doi:10.1073/pnas.96.11.6400
38. C. Communal, W. S. Colucci and K. Singh: p38 Mitogen-activated Protein Kinase Pathway Protects Adult Rat Ventricular Myocytes against �≤-Adrenergic Receptor-stimulated Apoptosis. J Biol Chem, 275, 19395-19400 (2000)
doi:10.1074/jbc.M910471199
PMid:10770956
39. W. Zhu, X. Zeng, M. Zheng and R.-P. Xiao: The Enigma of β2-Adrenergic Receptor Gi Signaling in the Heart: The Good, the Bad, and the Ugly. Circ Res, 97, 507-509 (2005)
doi:10.1161/01.RES.0000184615.56822.bd
PMid:16166560
40. M. R. Bristow, R. Ginsburg, W. Minobe, R. S. Cubicciotti, W. S. Sageman, K. Lurie, M. E. Billingham, D. C. Harrison and E. B. Stinson: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med, 307, 205-211 (1982)
doi:10.1056/NEJM198207223070401
PMid:6283349
41. G. S. Francis and J. N. Cohn: The autonomic nervous system in congestive heart failure. Annu Rev Med, 37, 235-47 (1986)
doi:10.1146/annurev.me.37.020186.001315
PMid:2871803
42. J. P. Maurice, A. S. Shah, A. P. Kypson, J. A. Hata, D. C. White, D. D. Glower and W. J. Koch: Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol, 276, H1853-H1860 (1999)
43. M. Ungerer, K. Kessebohm, K. Kronsbein, M. J. Lohse and G. Richardt: Activation of fl-Adrenergic Receptor Kinase During Myocardial Ischemia. Circ Res, 79, 455-460 (1996)
PMid:8781479
44. D. J. Choi, W. J. Koch, J. J. Hunter and H. A. Rockman: Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem, 272, 17223-17229 (1997)
doi:10.1074/jbc.272.27.17223
PMid:9202046
45. B. S. Manning, K. Shotwell, L. Mao, H. A. Rockman and W. J. Koch: Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy. Circulation, 102, 2751-2757 (2000)
PMid:11094043
46. G. Iaccarino, E. D. Tomhave, R. J. Lefkowitz and W. J. Koch: Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation, 98, 1783-1789 (1998)
PMid:9788834
47. G. Iaccarino, P. C. Dolber, R. J. Lefkowitz and W. J. Koch: Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. Hypertension, 33, 396-401 (1999)
PMid:9931136
48. J. A. Hata, M. L. Williams, J. N. Schroder, B. Lima, J. R. Keys, B. C. Blaxall, J. A. Petrofski, A. Jakoi, C. A. Milano and W. J. Koch: Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail, 12, 360-368 (2006)
doi:10.1016/j.cardfail.2006.02.011
PMid:16762799
49. G. Iaccarino, E. Barbato, E. Cipolletta, V. De Amicis, K. B. Margulies, D. Leosco, B. Trimarco and W. J. Koch: Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J, 26, 1752-1758 (2005)
doi:10.1093/eurheartj/ehi429
PMid:16055494
50. R. Gros, J. L. Benovic, C. M. Tan and R. D. Feldman: G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest, 99, 2087-2093 (1997)
doi:10.1172/JCI119381
PMid:9151780 PMCid:508038
51. R. E. Bonita, P. W. Raake, N. J. Otis, J. K. Chuprun, T. Spivack, A. Dasgupta, D. J. Whellan, P. J. Mather and W. J. Koch: Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci, 3, 14-18 (2010)
doi:10.1111/j.1752-8062.2010.00176.x
PMid:20443948
52. H. A. Rockman, K. R. Chien, D.J. Choi, G. Iaccarino, J. J. Hunter, J. Ross, R. J. Lefkowitz and W. J. Koch: Expression of a α-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A, 95, 7000-7005 (1998)
doi:10.1073/pnas.95.12.7000
53. V. B. Harding, L. R. Jones, R. J. Lefkowitz, W. J. Koch and H. A. Rockman: Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A, 98, 5809-5814 (2001)
doi:10.1073/pnas.091102398
PMid:11331748 PMCid:33295
54. K. Freeman, I. Lerman, E. G. Kranias, T. Bohlmeyer, M. R. Bristow, R. J. Lefkowitz, G. Iaccarino, W. J. Koch and L. A. Leinwand: Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest, 107, 967-974 (2001)
doi:10.1172/JCI12083
PMid:11306600 PMCid:199560
55. H. Tachibana, S. V. Naga Prasad, R. J. Lefkowitz, W. J. Koch and H. A. Rockman: Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation, 111, 591-597 (2005)
doi:10.1161/01.CIR.0000142291.70954.DF
PMid:15668342
56. S. V. Naga Prasad, G. Esposito, L. Mao, W. J. Koch and H. A. Rockman: Gα-dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy. J Biol Chem, 275, 4693-4698 (2000)
doi:10.1074/jbc.275.7.4693
PMid:10671499
57. L. G. Hommers, M. J. Lohse and M. B√�nemann: Regulation of the Inward Rectifying Properties of G-protein-activated Inwardly Rectifying K+ (GIRK) Channels by Gα Subunits. J Biol Chem, 278, 1037-1043 (2003)
doi:10.1074/jbc.M205325200
PMid:12403784
58. M. L. Williams, J. A. Hata, J. Schroder, E. Rampersaud, J. Petrofski, A. Jakoi, C. A. Milano and W. J. Koch: Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. Circulation, 109, 1590-1593 (2004)
doi:10.1161/01.CIR.0000125521.40985.28
PMid:15051637
59. D. C. White, J. A. Hata, A. S. Shah, D. D. Glower, R. J. Lefkowitz and W. J. Koch: Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A, 97, 5428-5433 (2000)
doi:10.1073/pnas.090091197
PMid:10779554
60. H. T. Tevaearai, A. D. Eckhart, K. F. Shotwell, K. Wilson and W. J. Koch: Ventricular dysfunction after cardioplegic arrest is improved after myocardial gene transfer of a beta-adrenergic receptor kinase inhibitor. Circulation, 104, 2069-2074 (2001)
doi:10.1161/hc4201.097188
PMid:11673348
61. S. A. Akhter, C. A. Skaer, A. P. Kypson, P. H. McDonald, K. C. Peppel, D. D. Glower, R. J. Lefkowitz and W. J. Koch: Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A, 94, 12100-12105 (1997)
doi:10.1073/pnas.94.22.12100
62. C. Zincarelli, S. Soltys, G. Rengo and J. E. Rabinowitz: Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 16, 1073-1080 (2008)
doi:10.1038/mt.2008.76
PMid:18414476
63. K. I. Berns and R. M. Linden: The cryptic life style of adeno-associated virus. Bioessays, 17, 237-245 (1995)
doi:10.1002/bies.950170310
PMid:7748178
64. G. Rengo, A. Lymperopoulos, C. Zincarelli, M. Donniacuo, S. Soltys, J. E. Rabinowitz and W. J. Koch: Myocardial Adeno-Associated Virus Serotype 6-βARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure. Circulation, 119, 89-98 (2009)
doi:10.1161/CIRCULATIONAHA.108.803999
PMid:19103992 PMCid:2647661
65. J. A. Pitcher, J. J. Tesmer, J. L. Freeman, W. D. Capel, W. C. Stone and R. J. Lefkowitz: Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J Biol Chem, 274, 34531-34534 (1999)
doi:10.1074/jbc.274.49.34531
PMid:10574913
66. M. Cong, S. J. Perry, F.-T. Lin, I. D. Fraser, L. A. Hu, W. Chen, J. A. Pitcher, J. D. Scott and R. J. Lefkowitz: Regulation of Membrane Targeting of the G Protein-coupled Receptor Kinase 2 by Protein Kinase A and Its Anchoring Protein AKAP79. J Biol Chem, 276, 15192-15199 (2001)
doi:10.1074/jbc.M009130200
PMid:11278469
67. T. T. Chuang, H. LeVine, 3rd and A. De Blasi: Phosphorylation and activation of beta-adrenergic receptor kinase by protein kinase C. J Biol Chem, 270, 18660-18665 (1995)
doi:10.1074/jbc.270.31.18660
PMid:7629197
68. C. Krasel, S. Dammeier, R. Winstel, J. Brockmann, H. Mischak and M. J. Lohse: Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin. J Biol Chem, 276, 1911-1915 (2001)
doi:10.1074/jbc.M008773200
PMid:11042191
69. T. T. Chuang, L. Paolucci and A. De Blasi: Inhibition of G protein-coupled receptor kinase subtypes by Ca2+/calmodulin. J Biol Chem, 271, 28691-28696 (1996)
doi:10.1074/jbc.271.45.28691
PMid:8910504
70. R. Malhotra, K. M. D'Souza, M. L. Staron, K. G. Birukov, I. Bodi and S. A. Akhter: G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. J Biol Chem, 285, 13748-13760 (2010)
doi:10.1074/jbc.M110.109272
PMid:20194499
71. E. J. Whalen, M. W. Foster, A. Matsumoto, K. Ozawa, J. D. Violin, L. G. Que, C. D. Nelson, M. Benhar, J. R. Keys, H. A. Rockman, W. J. Koch, Y. Daaka, R. J. Lefkowitz and J. S. Stamler: Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell, 129, 511-522 (2007)
PMid:10473590
72. L. Adam, M. Bouvier and T. L. Z. Jones: Nitric Oxide Modulates α-Adrenergic Receptor Palmitoylation and Signaling. J Biol Chem, 274, 26337-26343 (1999)
doi:10.1074/jbc.274.37.26337
PMid:16565729 PMCid:1751562
73. P. C. Leclerc, P. M. Lanctot, M. Auger-Messier, E. Escher, R. Leduc and G. Guillemette: S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II. Br J Pharmacol, 148, 306-313 (2006)
doi:10.1038/sj.bjp.0706725
PMid:19325130 PMCid:2669330
74. B. Lima, G. K. W. Lam, L. Xie, D. L. Diesen, N. Villamizar, J. Nienaber, E. Messina, D. Bowles, C. D. Kontos, J. M. Hare, J. S. Stamler and H. A. Rockman: Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci U S A, 106, 6297-6302 (2009)
doi:10.1073/pnas.0901043106
PMid:18691971 PMCid:2630185
75. K. Ozawa, E. J. Whalen, C. D. Nelson, Y. Mu, D. T. Hess, R. J. Lefkowitz and J. S. Stamler: S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking. Mol Cell, 31, 395-405 (2008)
doi:10.1016/j.molcel.2008.05.024
PMid:16432212 PMCid:1360548
76. G. Wang, N. H. Moniri, K. Ozawa, J. S. Stamler and Y. Daaka: Nitric oxide regulates endocytosis by S-nitrosylation of dynamin. Proc Natl Acad Sci U S A, 103, 1295-1300 (2006)
doi:10.1073/pnas.0508354103
PMid:20590581
77. P. Penela, C. Murga, C. Ribas, V. Lafarga and F. Mayor, Jr.: The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol, 160, 821-32 (2010)
PMid:9575184
78. J. A. Pitcher, R. A. Hall, Y. Daaka, J. Zhang, S. S. Ferguson, S. Hester, S. Miller, M. G. Caron, R. J. Lefkowitz and L. S. Barak: The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. J Biol Chem, 273, 12316-12324 (1998)
doi:10.1074/jbc.273.20.12316
PMid:12631274
79. N. Yoshida, K. Haga and T. Haga: Identification of sites of phosphorylation by G-protein-coupled receptor kinase 2 in beta-tubulin. Eur J Biochem, 270, 1154-1163 (2003)
doi:10.1046/j.1432-1033.2003.03465.x
PMid:18344371
80. G. Cheng, M. R. Zile, M. Takahashi, C. F. Baicu, D. D. Bonnema, F. Cabral, D. R. Menick and G. t. Cooper: A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. Am J Physiol Heart Circ Physiol, 294, H2231-H2241 (2008)
doi:10.1152/ajpheart.91515.2007
PMid:20080565 PMCid:2824312
81. P. Penela, V. n. Rivas, A. Salcedo and F. Mayor: G protein-coupled receptor kinase 2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci U S A, 107, 1118-1123 (2010)
doi:10.1073/pnas.0905778107
PMid:16142243
82. S. Liu, R. T. Premont, C. D. Kontos, S. Zhu and D. C. Rockey: A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med, 11, 952-958 (2005)
doi:10.1038/nm1289
PMid:10376602
83. D. Fulton, J. P. Gratton, T. J. McCabe, J. Fontana, Y. Fujio, K. Walsh, T. F. Franke, A. Papapetropoulos and W. C. Sessa: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 399, 597-601 (1999)
doi:10.1038/21218
PMid:10376603
84. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse and A. M. Zeiher: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399, 601-605 (1999)
doi:10.1038/21224
PMid:10085129
85. C. V. Carman, M. P. Lisanti and J. L. Benovic: Regulation of G protein-coupled receptor kinases by caveolin. J Biol Chem, 274, 8858-8864 (1999)
doi:10.1074/jbc.274.13.8858
PMid:11389137
86. T. Shiina, K. Arai, S. Tanabe, N. Yoshida, T. Haga, T. Nagao and H. Kurose: Clathrin Box in G Protein-coupled Receptor Kinase 2. J Biol Chem, 276, 33019-33026 (2001)
doi:10.1074/jbc.M100140200
PMid:17322894
87. A. Lymperopoulos, G. Rengo, H. Funakoshi, A. D. Eckhart and W. J. Koch: Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med, 13, 315-323 (2007)
doi:10.1038/nm1553
PMid:18223549
88. A. Lymperopoulos, G. Rengo, C. Zincarelli, S. Soltys and W. J. Koch: Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther, 16, 302-307 (2008)
doi:10.1038/sj.mt.6300371
PMid:20351116
89. A. Lymperopoulos, G. Rengo, E. Gao, S. N. Ebert, G. W. Dorn, 2nd and W. J. Koch: Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem, 285, 16378-16386 (2010)
doi:10.1074/jbc.M109.077859
90. H. A. Rockman, D. J. Choi, N. U. Rahman, S. A. Akhter, R. J. Lefkowitz and W. J. Koch: Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A, 93, 9954-9959 (1996)
doi:10.1073/pnas.93.18.9954
PMid:10625304
91. A. D. Eckhart, S. J. Duncan, R. B. Penn, J. L. Benovic, R. J. Lefkowitz and W. J. Koch: Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res, 86, 43-50 (2000)
PMid:12052842
92. X. P. Yi, A. M. Gerdes and F. Li: Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension, 39, 1058-1063 (2002)
doi:10.1161/01.HYP.0000019130.09167.3B
PMid:15584034
93. X. P. Yi, J. Zhou, J. Baker, X. Wang, A. M. Gerdes and F. Li: Myocardial expression and redistribution of GRKs in hypertensive hypertrophy and failure. Anat Rec A Discov Mol Cell Evol Biol, 282, 13-23 (2005)
PMid:11114197
94. T. A. McKinsey, C. L. Zhang and E. N. Olson: Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci U S A, 97, 14400-14405 (2000)
doi:10.1073/pnas.260501497
PMid:15367668 PMCid:516756
95. S. Chang, T. A. McKinsey, C. L. Zhang, J. A. Richardson, J. A. Hill and E. N. Olson: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol, 24, 8467-8476 (2004)
doi:10.1128/MCB.24.19.8467-8476.2004
PMid:18425130 PMCid:2596476
96. C. L. Zhang, T. A. McKinsey, S. Chang, C. L. Antos, J. A. Hill and E. N. Olson: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 110, 479-488 (2002)
PMid:9218466
97. S. B. Liggett, S. Cresci, R. J. Kelly, F. M. Syed, S. J. Matkovich, H. S. Hahn, A. Diwan, J. S. Martini, L. Sparks, R. R. Parekh, J. A. Spertus, W. J. Koch, S. L. Kardia and G. W. Dorn, 2nd: A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med, 14, 510-517 (2008)
doi:10.1038/nm1750
PMid:9753452
98. A. N. Pronin, D. K. Satpaev, V. Z. Slepak and J. L. Benovic: Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain. J Biol Chem, 272, 18273-18280 (1997)
doi:10.1074/jbc.272.29.18273
PMid:17786238 PMCid:1952636
99. K. Levay, D. K. Satpaev, A. N. Pronin, J. L. Benovic and V. Z. Slepak: Localization of the sites for Ca2+-binding proteins on G protein-coupled receptor kinases. Biochemistry, 37, 13650-13659 (1998)
doi:10.1021/bi980998z
PMid:17157248
100. T. Noma, A. Lemaire, S. V. Naga Prasad, L. Barki-Harrington, D. G. Tilley, J. Chen, P. Le Corvoisier, J. D. Violin, H. Wei, R. J. Lefkowitz and H. A. Rockman: Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest, 117, 2445-2458 (2007)
doi:10.1172/JCI31901
PMid:17482545
101. R. J. Lefkowitz, K. Rajagopal and E. J. Whalen: New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell, 24, 643-652 (2006)
doi:10.1016/j.molcel.2006.11.007
PMid:12202037
Abbreviations: HF: Heart failure, GPCR: G protein-coupled receptor, GRK: GPCR kinase, βAR: β-adrenergic receptor, AT1R: angiotensin II receptors, ET1R: endothelin-1 receptor, PKA: protein kinase A, PKC: protein kinase C, PIP2: phosphatidylinositol 4,5-bisphosphate, CSQ: calsequestrin, MI: myocardial infarction, TAC: transverse aortic constriction, CARP: cardiac ankyrin repeat protein, PI3K: phosphatidylinositol 3-kinase, IK,Ach: acetylcholine activated K+ channels, AAV: adeno-associated virus, eNOS: endothelial nitric oxide synthase, MEF2: myocyte elongation factor 2, HDAC: histone deacetylase, NLS: nuclear localization sequence, NES: nuclear export sequence, SNP: single nucleotide polymorphism, EGF: epidermal growth factor
Key Words: Beta-adrenergic receptor, heart failure, G protein-coupled receptor kinases, βARKct, desensitization, cardioprotection, Review
Send correspondence to: Walter J. Koch, Center for Translational Medicine, Thomas Jefferson University, 1025 Walnut St, Room 317, Philadelphia, PA 19107, Tel: 215-955-9982, Fax: 215-503-5731, E-mail: walter.koch@jefferson.edu